Articles
Page 14 of 20
-
Citation: BMC Pharmacology 2007 7(Suppl 1):P68
-
A luminescence-based assay for sensitive nitric oxide detection
Citation: BMC Pharmacology 2007 7(Suppl 1):P66 -
Activation of the nitric oxide-cGMP signaling pathway precedes resolution in acute anti-thy1 glomerulonephritis
Citation: BMC Pharmacology 2007 7(Suppl 1):P63 -
Ultraviolet B light initiating activity of two-stage mouse skin carcinogenesis and its regulation of cGMP
Citation: BMC Pharmacology 2007 7(Suppl 1):P61 -
The effects of chronic sildenafil therapy in patients with stable systolic heart failure
Citation: BMC Pharmacology 2007 7(Suppl 1):P59 -
Vardenafil improves myocardial and endothelial function after cardiopulmonary bypass
Citation: BMC Pharmacology 2007 7(Suppl 1):P57 -
New human alpha1 soluble guanylyl cyclase splice variants as potential regulators of sGC activity
Citation: BMC Pharmacology 2007 7(Suppl 1):P55 -
NO/cGMP/PKG pathway in platelets: inhibitory but not stimulatory
Citation: BMC Pharmacology 2007 7(Suppl 1):S50 -
S-nitrosylation of soluble guanylyl cyclase: a novel mechanism of nitrate tolerance?
Citation: BMC Pharmacology 2007 7(Suppl 1):P49 -
Signaling of NO/cGMP via IRAG
Citation: BMC Pharmacology 2007 7(Suppl 1):S49 -
cGMP-dependent and -independent angiogenesis-related properties of nitric oxide
Citation: BMC Pharmacology 2007 7(Suppl 1):P47 -
cGMP kinase and food-related behaviours
Citation: BMC Pharmacology 2007 7(Suppl 1):S46 -
Protein kinase G phosphorylates soluble guanylyl cyclase and inhibits its activity
Citation: BMC Pharmacology 2007 7(Suppl 1):P45 -
Functional roles of isoforms of NO-sensitive guanylyl cyclase
Citation: BMC Pharmacology 2007 7(Suppl 1):S44 -
FRET-based method for rapid screening of PDE-inhibitors in living cells
Citation: BMC Pharmacology 2007 7(Suppl 1):P43 -
sGC activation promotes angiogenesis
Citation: BMC Pharmacology 2007 7(Suppl 1):S42 -
Regulation of cardiovascular physiology by cyclic GMP-dependent protein kinase Iα
Citation: BMC Pharmacology 2007 7(Suppl 1):S40 -
Effects of vardenafil, a selective phosphodiesterase-5-inhibitor, on cardiovascular function in a rat model
Citation: BMC Pharmacology 2007 7(Suppl 1):P39 -
Dynamic ligand exchange as mechanism for sGC selectivity, NO activation and its reversal
Citation: BMC Pharmacology 2007 7(Suppl 1):S38 -
Cardiorenal actions of a novel chimeric natriuretic peptide, CD-NP, as compared to C-type natriuretic peptide, in the normal dog
Citation: BMC Pharmacology 2007 7(Suppl 1):P37 -
Insights into activation and dimerization of soluble guanylate cyclase
Citation: BMC Pharmacology 2007 7(Suppl 1):S36 -
Vardenafil limits infarction at reperfusion in isolated rat hearts dependent on guanylyl cyclase and PKG
Citation: BMC Pharmacology 2007 7(Suppl 1):P35 -
Oxidative stress induces CHIP-mediated ubiquitination and roteasomal degradation of soluble guanylyl cyclase
Citation: BMC Pharmacology 2007 7(Suppl 1):S34 -
Inhibitors of cAMP and cGMP phosphodiesterases enhance neurite outgrowth from cultured cortical neurons in a PKG dependent manner
Citation: BMC Pharmacology 2007 7(Suppl 1):P33 -
Translational research of natriuretic peptide family
Citation: BMC Pharmacology 2007 7(Suppl 1):S32 -
The nitroxyl anion (HNO) donor, Angeli's salt, does not develop tolerance in vivo
Citation: BMC Pharmacology 2007 7(Suppl 1):P31 -
Negative feedback control of the nitric oxide/cGMP pathway in smooth muscle
Citation: BMC Pharmacology 2007 7(Suppl 1):S30 -
Increased mesangial cGMP levels prevent mesangial cell proliferation and matrix expansion in experimental glomerulonephritis
Citation: BMC Pharmacology 2007 7(Suppl 1):P29 -
Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses endothelial dysfunction and oxidative stress associated with the metabolic syndrome
Citation: BMC Pharmacology 2007 7(Suppl 1):S28 -
A luminescence based biochemical assay for soluble guanylyl cyclase
Citation: BMC Pharmacology 2007 7(Suppl 1):P27 -
In vivo evidence that cyclic GMP-dependent protein kinase G type I α mediates an anti-hypertrophic pathway in the heart
Citation: BMC Pharmacology 2007 7(Suppl 1):S26 -
Lack of NO-mediated NANC relaxation in mice deficient in NO-sensitive guanylyl cyclase
Citation: BMC Pharmacology 2007 7(Suppl 1):P24 -
Design and characterization of FRET-based cGMP indicators
Citation: BMC Pharmacology 2007 7(Suppl 1):S24 -
Physiological and pathological effects of complete sGC deletion
Citation: BMC Pharmacology 2007 7(Suppl 1):P22 -
FlincGs: novel, non-FRET cGMP biosensors with nanomolar sensitivity for NO-induced signaling
Citation: BMC Pharmacology 2007 7(Suppl 1):S22 -
A mouse (and chips) model for NO-activated guanylyl cyclase
Citation: BMC Pharmacology 2007 7(Suppl 1):S20 -
Receptor guanylyl cyclase-G-deficient mice are protected against renal ischemia-reperfusion injury by preventing apoptosis and inflammation
Citation: BMC Pharmacology 2007 7(Suppl 1):S18 -
Reperfusion lung injury is attenuated by natriuretic peptide receptor antagonist in in-vivo mouse model
Citation: BMC Pharmacology 2007 7(Suppl 1):P16 -
Transgenic mice with a NO-insensitive soluble guanylate cyclase
Citation: BMC Pharmacology 2007 7(Suppl 1):S16 -
Analysis of smooth muscle function in IRAG knockout mice
Citation: BMC Pharmacology 2007 7(Suppl 1):P14 -
Modulating cGMP in heart failure
Citation: BMC Pharmacology 2007 7(Suppl 1):S14 -
Restoration of learning in hepatic encephalopathy by pharmacological manipulation of cGMP levels in brain
Citation: BMC Pharmacology 2007 7(Suppl 1):S13 -
Coadministration of B-type natriuretic peptide and the vasopressin-2 receptor antagonist tolvaptan: a novel physiologic strategy to enhance water and sodium excretion without adversely affecting renal or neurohumoral function in experimental congestive heart failure
Citation: BMC Pharmacology 2007 7(Suppl 1):P12 -
Clinical trials with urodilatin in patients with acute decompensated heart failure
Citation: BMC Pharmacology 2007 7(Suppl 1):S11 -
Opposite effects of cGMP-dependent protein kinase on cGMP production by soluble and particular guanylyl cyclase in adult ventricular myocytes
Citation: BMC Pharmacology 2007 7(Suppl 1):P10 -
Activation of soluble guanylate cyclase in the presence of purified human aldehyde dehydrogenases
Citation: BMC Pharmacology 2007 7(Suppl 1):P7 -
Oxidised sGC: a novel therapeutic target in the vasculature
Citation: BMC Pharmacology 2007 7(Suppl 1):S5 -
sGC stimulators in experimental pulmonary hypertension
Citation: BMC Pharmacology 2007 7(Suppl 1):S3 -
Selective modulation of ANP-dependent dilatation in the pulmonary vasculature by PDE 5 inhibitors: a novel combination therapy for pulmonary hypertension?
Citation: BMC Pharmacology 2007 7(Suppl 1):P2 -
Characterization of tandem GAF domains of phosphodiesterases
Citation: BMC Pharmacology 2007 7(Suppl 1):S1